Table 1.
Neoadjuvant and adjuvant therapy in locally advanced gastric cancer
| n | Setting | Arm | DFS (%) | P value | OS (%) | P value | |
|---|---|---|---|---|---|---|---|
| Cunningham et al5 | 250/253 | Perioperative | POC/S | 30/18 | <0.001 | 36.3/29.5 | =0.009 |
| Ychou et al6 | 113/111 | Perioperative | POC/S | 34/19 | =0.003 | 38/24 | =0.021 |
| Schuhmacher et al7 | 72/72 | Neoadjuvant | NC + S/S | – | NS | – | NS |
| Nakajima et al8 | 95/95 | Adjuvant | S + UFT/S | – | – | 86/73 | 0.017 |
| Sakuramoto et al9 | 529/530 | Adjuvant | S + S-1/S | – | – | 80.1/70.1 | 0.003 |
| MacDonald et al11 | 281/275 | Adjuvant | S + CR/S | 48/31 | <0.001 | 50/41 | 0.005 |
Abbreviations: DFS, disease-free survival; OS, overall survival; POC, perioperative chemotherapy; S, surgery; NC, neoadjuvant; CR, chemoradiotherapy.